文献速递细菌感染、耐药与抗菌药物

巴基斯坦2015-17年抗生素耐药性调查(SOAR):基于CLSI、EUCAST(剂量特异性)和PK/PD折点的数据

Results from the Survey of Antibiotic Resistance (SOAR) 2015-17 in Pakistan: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
PubMed 文献 · J Antimicrob Chemother · 2020-01-01

该研究测定了2015-17年巴基斯坦社区获得性呼吸道感染(CA-RTI)分离的肺炎链球菌和流感嗜血杆菌的抗生素敏感性,使用CLSI、EUCAST(剂量特异性)和PK/PD折点进行评估。结果显示,不同折点下敏感性差异显著,尤其是口服头孢呋辛和氟喹诺酮类。这些数据对CA-RTI的经验性治疗选择具有重要意义。

要点

  • 肺炎链球菌对青霉素敏感性低(CLSI口服/EUCAST低剂量IV折点仅23.4%),但CLSI IV和EUCAST高剂量折点下全部敏感。
  • 流感嗜血杆菌几乎均为β-内酰胺酶阴性(96.7%),CLSI折点下多数抗生素敏感性≥93.4%,但氟喹诺酮类和复方磺胺甲噁唑较低。
  • EUCAST折点下部分抗生素敏感性显著降低,如口服头孢呋辛仅1.6%敏感,氟喹诺酮类33.6%-34.4%。

核心结论

  • 在巴基斯坦,这些重要呼吸道病原体的抗生素敏感性因不同折点而异,数据对CA-RTI经验性治疗选择重要。

研究设计与样本

  • 研究收集了2015-17年巴基斯坦的94株肺炎链球菌和122株流感嗜血杆菌,通过CLSI肉汤微量稀释法测定MIC,并采用CLSI、EUCAST(剂量特异性)和PK/PD折点评估敏感性。

主要发现

  • 肺炎链球菌对青霉素敏感性在CLSI口服/EUCAST低剂量IV折点下为23.4%,CLSI IV和EUCAST高剂量折点下全部敏感。
  • 肺炎链球菌对复方磺胺甲噁唑(10.6%)、大环内酯类(33%)和头孢克洛(28.7%)敏感性低,对头孢曲松(100%)、阿莫西林和阿莫西林/克拉维酸(98.9%)、口服头孢呋辛(97.9%)、头孢泊肟(96.8%)、氟喹诺酮类(93.6%-96.8%)和头孢地尼(76.6%)敏感性较高(CLSI折点)。
  • EUCAST折点下,肺炎链球菌对头孢泊肟(70.2%)和口服头孢呋辛(61.7%)敏感性降低。
  • 流感嗜血杆菌几乎均为β-内酰胺酶阴性(96.7%),CLSI折点下除氟喹诺酮类(75.4%-77.1%)和复方磺胺甲噁唑(41%)外,所有测试抗生素敏感性≥93.4%。
  • EUCAST折点下,流感嗜血杆菌对口服头孢呋辛仅1.6%敏感,对氟喹诺酮类敏感性为33.6%-34.4%。

关键数值与推荐

  • 肺炎链球菌对青霉素敏感性:CLSI口服/EUCAST低剂量IV折点23.4%,CLSI IV和EUCAST高剂量折点100%。
  • 肺炎链球菌对头孢曲松敏感性100%,阿莫西林和阿莫西林/克拉维酸98.9%,口服头孢呋辛97.9%,头孢泊肟96.8%,氟喹诺酮类93.6%-96.8%,头孢地尼76.6%(CLSI折点)。
  • EUCAST折点下肺炎链球菌对头孢泊肟敏感性70.2%,口服头孢呋辛61.7%。
  • 流感嗜血杆菌β-内酰胺酶阴性率96.7%,CLSI折点下对测试抗生素(除氟喹诺酮类和复方磺胺甲噁唑)敏感性≥93.4%。
  • EUCAST折点下流感嗜血杆菌对口服头孢呋辛敏感性1.6%,对氟喹诺酮类敏感性33.6%-34.4%。

临床怎么用

  • 在巴基斯坦CA-RTI经验性治疗中,应依据当地耐药数据和折点选择抗生素,考虑剂量对敏感性的影响。

局限性

  • 研究仅基于巴基斯坦2015-17年的分离株,结果可能不适用于其他地区或时期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine antibiotic susceptibility of community-acquired respiratory tract infection (CA-RTI) isolates of Streptococcus pneumoniae and Haemophilus influenzae collected in 2015-17 from Pakistan. METHODS: MICs were determined by CLSI broth microdilution and susceptibility was assessed using CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. RESULTS: A total of 94 S. pneumoniae and 122 H. influenzae isolates were collected. Susceptibility to penicillin was noted in 23.4% of the S. pneumoniae isolates by CLSI oral/EUCAST low-dose IV breakpoints, although by CLSI IV and EUCAST high-dose breakpoints all isolates were characterized as susceptible. Susceptibility to trimethoprim/sulfamethoxazole (10.6%), macrolides (33%) and cefaclor (28.7%) was low but higher susceptibility was observed to ceftriaxone (100%), amoxicillin and amoxicillin/clavulanic acid (98.9%), cefuroxime (oral, 97.9%), cefpodoxime (96.8%), fluoroquinolones (93.6%-96.8%) and cefdinir (76.6%) by CLSI breakpoints. However, using EUCAST breakpoints, susceptibility to cefpodoxime (70.2%) and cefuroxime (oral, 61.7%) was reduced. H. influenzae isolates were almost all β-lactamase negative (96.7%). Using CLSI breakpoints, ≥93.4% of isolates were susceptible to all antibiotics tested except fluoroquinolones (75.4%-77.1%) and trimethoprim/sulfamethoxazole (41%). The proportion of isolates susceptible using EUCAST breakpoints was similar or identical for penicillins, trimethoprim/sulfamethoxazole and the cephalosporins that have EUCAST breakpoints; the proportion of isolates susceptible using EUCAST breakpoints was similar or identical to that using CSLI breakpoints except for cefuroxime (oral), where only 1.6% of isolates were considered susceptible. Susceptibility of H. influenzae to fluoroquinolones was also lower by EUCAST breakpoints (33.6%-34.4%). The application of different EUCAST breakpoints for low and higher doses for some of the antibiotics (amoxicillin, amoxicillin/clavulanic acid, ampicillin, penicillin, ceftriaxone, clarithromycin, erythromycin, levofloxacin and trimethoprim/sulfamethoxazole) allowed, for the first time in a SOAR study, the effect of raising the dosage on susceptibility to be quantified. CONCLUSIONS: Antibiotic susceptibility in these important respiratory tract pathogens varied in Pakistan based on different breakpoints. These data are important for empirical therapy choices in the treatment of CA-RTIs.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Torumkuney D, Anwar S, Nizamuddin S, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2015-17 in Pakistan: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. J Antimicrob Chemother. 2020. PMID: 32337594. doi:10.1093/jac/dkaa085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。